Pasi A. Jänne

Pasi A. Jänne, MD, PhD, is the Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School, widely regarded as one of the world's preeminent investigators in EGFR-driven lung cancer biology and therapy. His laboratory has made foundational discoveries in the mechanisms of EGFR inhibitor resistance, including the characterization of the EGFR T790M gatekeeper mutation as the dominant acquired resistance mechanism to first-generation EGFR inhibitors, a finding that directly catalyzed the development of third-generation agents including osimertinib. He has been a central figure in osimertinib clinical development from its earliest phases through approval in multiple settings. Jänne's laboratory employs a translational approach combining genomic profiling of patient-derived resistance biopsies, patient-derived cell lines, and xenograft models to dissect the molecular mechanisms of acquired resistance to each generation of EGFR-targeted therapy. His work has continuously fed back into clinical trial design, informing rational combination and sequential therapy strategies. Beyond EGFR, he has contributed importantly to the development of KRAS G12C inhibitors including adagrasib, and to the biology of HER2 alterations in lung cancer, reflecting his broad expertise in receptor tyrosine kinase signaling in thoracic malignancies. Jänne has served on multiple editorial boards and guideline committees, received numerous honors recognizing his translational contributions, and trained a large number of investigators now leading their own programs. His career trajectory from bench discovery to transformative clinical trials has set a model for translational science in oncology.